{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T21:47:18Z","timestamp":1767304038575},"reference-count":53,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The wide clinical spectrum of von Willebrand disease (VWD), its complex pathophysiology and its classification into distinct quantitative (type 1 or type 3) and qualitative (type 2) types with further subtle distinctions have prevented most clinicians from establishing a straightforward approach to diagnosing and treating this inherited bleeding disorder. The results of studies involving large cohorts of patients with a wide range of bleeding manifestations and variable von Willebrand factor (VWF) reduction have recently become available. These data have allowed the proposal of minimal criteria for a clinically useful diagnosis and for differentiating patients with mild VWD from subjects with borderline or only slightly reduced VWF levels who will not benefit from a specific diagnosis. These criteria are based on measurement of VWF ristocetin cofactor (VWF:RCo), VWF antigen (VWF:Ag), factor VIII and a standardized bleeding score (BS). Demonstration of the inheritance of the disorder could help to classify patients for whom insufficient hemostatic challenges may produce a falsely reassuring BS (like in children). Using this approach, mild VWD appears to be mostly composed of type 1 cases. Complemented by the results of desmopressin trial infusion, these parameters form the basis for a clinically oriented classification of all forms of VWD and may be useful for selecting the best treatment according to the severity of the disease. Although few molecular data have revealed practical utility, there is no doubt that the clarification of the molecular pathophysiology of VWD has allowed the unification of this complex disorder into a simple conceptual framework. This framework underlies the proposed utilization of simple phenotypic markers for optimizing treatments in individual patients.<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.113","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T20:35:31Z","timestamp":1260563731000},"page":"113-123","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Optimizing treatment of von Willebrand disease by using phenotypic and molecular data"],"prefix":"10.1182","volume":"2009","author":[{"given":"Francesco","family":"Rodeghiero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Tosetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111703043817900_R1","doi-asserted-by":"crossref","unstructured":"Wu YP, Vink T, Schiphorst M, et al. Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor-glycoprotein Ib interaction and inhibited by von Willebrand factor-glycoprotein IIb\/IIIa interaction. Arterioscler Thromb Vasc Biol. 2000;20:1661\u20131667.","DOI":"10.1161\/01.ATV.20.6.1661"},{"key":"2019111703043817900_R2","doi-asserted-by":"crossref","unstructured":"Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood. 2006;107:3537\u20133545.","DOI":"10.1182\/blood-2005-02-0618"},{"key":"2019111703043817900_R3","doi-asserted-by":"crossref","unstructured":"Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217\u2013246.","DOI":"10.1146\/annurev.cb.06.110190.001245"},{"key":"2019111703043817900_R4","doi-asserted-by":"crossref","unstructured":"Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223\u20134234.","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223"},{"key":"2019111703043817900_R5","doi-asserted-by":"crossref","unstructured":"Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103\u20132114.","DOI":"10.1111\/j.1538-7836.2006.02146.x"},{"key":"2019111703043817900_R6","doi-asserted-by":"crossref","unstructured":"Budde U, Schneppenheim R, Eikenboom J, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost. 2008;6:762\u2013771.","DOI":"10.1111\/j.1538-7836.2008.02945.x"},{"key":"2019111703043817900_R7","doi-asserted-by":"crossref","unstructured":"Eikenboom JC, Reitsma PH, Peerlinck KM, Briet E. Recessive inheritance of von Willebrand\u2019s disease type I. Lancet. 1993;341:982\u2013986.","DOI":"10.1016\/0140-6736(93)91070-3"},{"key":"2019111703043817900_R8","doi-asserted-by":"crossref","unstructured":"Eikenboom J, Van Marion V, Putter H, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost. 2006;4:774\u2013782.","DOI":"10.1111\/j.1538-7836.2006.01823.x"},{"key":"2019111703043817900_R9","doi-asserted-by":"crossref","unstructured":"Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with Type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of Type 1 von Willebrand disease (MCMDM-1VWD). Blood. 2007;109:112\u2013121.","DOI":"10.1182\/blood-2006-05-020784"},{"key":"2019111703043817900_R10","doi-asserted-by":"crossref","unstructured":"James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood. 2007;109:145\u2013154.","DOI":"10.1182\/blood-2006-05-021105"},{"key":"2019111703043817900_R11","doi-asserted-by":"crossref","unstructured":"Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood. 2003;101:2089\u20132093.","DOI":"10.1182\/blood-2002-09-2892"},{"key":"2019111703043817900_R12","doi-asserted-by":"crossref","unstructured":"Castaman G, Tosetto A, Rodeghiero F. von Willebrand disease. In: O\u2019Shaughnessy D, Makris M, Lillicrap D, eds. Practical Hemostasis and Thrombosis. Blackwell; 2005:51\u201361.","DOI":"10.1002\/9780470988633.ch6"},{"key":"2019111703043817900_R13","doi-asserted-by":"crossref","unstructured":"Mazurier C. von Willebrand disease masquerading as haemophilia A. Thromb Haemost. 1992;67:391\u2013396.","DOI":"10.1055\/s-0038-1648458"},{"key":"2019111703043817900_R14","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Tosetto A, Castaman G. How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost. 2007;5 (Suppl 1):157\u2013166.","DOI":"10.1111\/j.1538-7836.2007.02520.x"},{"key":"2019111703043817900_R15","doi-asserted-by":"crossref","unstructured":"Sadler J, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1; on behalf of the SSC Subcommittee on von Willebrand factor. J Thromb Haemost. 2005;3:775\u2013777.","DOI":"10.1111\/j.1538-7836.2005.01245.x"},{"key":"2019111703043817900_R16","doi-asserted-by":"crossref","unstructured":"Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14:171\u2013232.","DOI":"10.1111\/j.1365-2516.2007.01643.x"},{"key":"2019111703043817900_R17","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of von Willebrand disease type 1: an international, multicenter study. J Thromb Haemost. 2005;3:2619\u20132626.","DOI":"10.1111\/j.1538-7836.2005.01663.x"},{"key":"2019111703043817900_R18","doi-asserted-by":"crossref","unstructured":"Castaman G, Rodeghiero F, Tosetto A, et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost. 2006;4:2164\u20132169.","DOI":"10.1111\/j.1538-7836.2006.02070.x"},{"key":"2019111703043817900_R19","doi-asserted-by":"crossref","unstructured":"Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysys of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4:766\u2013773.","DOI":"10.1111\/j.1538-7836.2006.01847.x"},{"key":"2019111703043817900_R20","doi-asserted-by":"crossref","unstructured":"Tosetto A, Rodeghiero F, Castaman G, et al. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multi-center European study (MCMDM-1VWD). J Thromb Haemost. 2007;5:715\u2013721.","DOI":"10.1111\/j.1538-7836.2007.02444.x"},{"key":"2019111703043817900_R21","doi-asserted-by":"crossref","unstructured":"Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood. 2008;111:3998\u20134003.","DOI":"10.1182\/blood-2007-08-105940"},{"key":"2019111703043817900_R22","doi-asserted-by":"crossref","unstructured":"Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score. Blood Rev. 2007;21:89\u201397.","DOI":"10.1016\/j.blre.2006.04.002"},{"key":"2019111703043817900_R23","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood. 2009:114:1158\u20131165.","DOI":"10.1182\/blood-2009-01-153296"},{"key":"2019111703043817900_R24","doi-asserted-by":"crossref","unstructured":"Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia. 2008;14 Suppl 5:47\u201353.","DOI":"10.1111\/j.1365-2516.2008.01851.x"},{"key":"2019111703043817900_R25","doi-asserted-by":"crossref","unstructured":"James PD, Paterson AD, Notley C, et al. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost. 2006;4:783\u2013792.","DOI":"10.1111\/j.1538-7836.2006.01860.x"},{"key":"2019111703043817900_R26","doi-asserted-by":"crossref","unstructured":"Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111:4979\u20134985.","DOI":"10.1182\/blood-2007-09-110940"},{"key":"2019111703043817900_R27","doi-asserted-by":"crossref","unstructured":"Gralnick HR, Williams SB, McKeown LP, et al. DDAVP in type IIa von Willebrand\u2019s disease. Blood. 1986;67:465\u2013468.","DOI":"10.1182\/blood.V67.2.465.465"},{"key":"2019111703043817900_R28","doi-asserted-by":"crossref","unstructured":"Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113:526\u2013534.","DOI":"10.1182\/blood-2008-04-152280"},{"key":"2019111703043817900_R29","doi-asserted-by":"crossref","unstructured":"Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol. 2001;14:337\u2013347.","DOI":"10.1053\/beha.2001.0138"},{"key":"2019111703043817900_R30","doi-asserted-by":"crossref","unstructured":"Mazurier C, Gaucher C, Jorieux S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N (\u2018Normandy\u2019) von Willebrand disease. Collaborative Group. Br J Haematol. 1994;88:849\u2013854.","DOI":"10.1111\/j.1365-2141.1994.tb05127.x"},{"key":"2019111703043817900_R31","doi-asserted-by":"crossref","unstructured":"Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008;111:3531\u20133539.","DOI":"10.1182\/blood-2007-08-109231"},{"key":"2019111703043817900_R32","doi-asserted-by":"crossref","unstructured":"Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol. 2001;14:365\u2013379.","DOI":"10.1053\/beha.2001.0139"},{"key":"2019111703043817900_R33","unstructured":"Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med. 1995;125:348\u2013355."},{"key":"2019111703043817900_R34","doi-asserted-by":"crossref","unstructured":"Casonato A, Pontara E, Sartorello F, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood. 2002;99:180\u2013184.","DOI":"10.1182\/blood.V99.1.180"},{"key":"2019111703043817900_R35","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G. Treatment of von Willebrand disease. Semin Hematol. 2005;42:29\u201335.","DOI":"10.1053\/j.seminhematol.2004.10.001"},{"key":"2019111703043817900_R36","doi-asserted-by":"crossref","unstructured":"Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood. 1992;79:3130\u20133137.","DOI":"10.1182\/blood.V79.12.3130.3130"},{"key":"2019111703043817900_R37","doi-asserted-by":"crossref","unstructured":"Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand\u2019s disease. Thromb Haemost. 2002;88:387\u2013388.","DOI":"10.1055\/s-0037-1613227"},{"key":"2019111703043817900_R38","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Treatment of von Willebrand\u2019s disease. N Engl J Med. 2004;351:683\u2013694.","DOI":"10.1056\/NEJMra040403"},{"key":"2019111703043817900_R39","doi-asserted-by":"crossref","unstructured":"Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet. 1998;351:485\u2013489.","DOI":"10.1016\/S0140-6736(97)08248-2"},{"key":"2019111703043817900_R40","doi-asserted-by":"crossref","unstructured":"Rodeghiero F. Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin [review]. Haemophilia. 2008;14:21\u201330.","DOI":"10.1111\/j.1365-2516.2007.01611.x"},{"key":"2019111703043817900_R41","doi-asserted-by":"crossref","unstructured":"Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG. 2004;111:1425\u20131428.","DOI":"10.1111\/j.1471-0528.2004.00305.x"},{"key":"2019111703043817900_R42","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost. 1996;76:692\u2013696.","DOI":"10.1055\/s-0038-1650645"},{"key":"2019111703043817900_R43","doi-asserted-by":"crossref","unstructured":"Leissinger C, Becton D, Cornell C Jr, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001;7:258\u2013266.","DOI":"10.1046\/j.1365-2516.2001.00500.x"},{"key":"2019111703043817900_R44","doi-asserted-by":"crossref","unstructured":"Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia. 2002;8:787\u2013793.","DOI":"10.1046\/j.1365-2516.2002.00678.x"},{"key":"2019111703043817900_R45","doi-asserted-by":"crossref","unstructured":"Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995;74:784\u2013790.","DOI":"10.1055\/s-0038-1649813"},{"key":"2019111703043817900_R46","doi-asserted-by":"crossref","unstructured":"James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost. 2007;5:1165\u20131169.","DOI":"10.1111\/j.1538-7836.2007.02563.x"},{"key":"2019111703043817900_R47","doi-asserted-by":"crossref","unstructured":"Castaman G, Bertoncello K, Bernardi M, Rodeghiero F. Pregnancy and delivery in patients with homozygous or heterozygous R854Q type 2N von Willebrand disease. J Thromb Haemost. 2005;3:391\u2013392.","DOI":"10.1111\/j.1538-7836.2005.01162.x"},{"key":"2019111703043817900_R48","doi-asserted-by":"crossref","unstructured":"Castaman G, Eikenboom JC, Contri A, Rodeghiero F. Pregnancy in women with type 1 von Willebrand disease caused by heterozygosity for von Willebrand factor mutation C1130F. Thromb Haemost. 2000;84:351\u2013352.","DOI":"10.1055\/s-0037-1614020"},{"key":"2019111703043817900_R49","doi-asserted-by":"crossref","unstructured":"Castaman G, Federici AB, Bernardi M, Moroni B, Bertoncello K, Rodeghiero F. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect. J Thromb Haemost. 2006;4:357\u2013360.","DOI":"10.1111\/j.1538-7836.2006.01706.x"},{"key":"2019111703043817900_R50","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand\u2019s disease. Blood. 1987;69:454\u2013459.","DOI":"10.1182\/blood.V69.2.454.454"},{"key":"2019111703043817900_R51","unstructured":"Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand\u2019s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica. 2003;88:94\u2013108."},{"key":"2019111703043817900_R52","doi-asserted-by":"crossref","unstructured":"Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem. 1992;267:4424\u20134430.","DOI":"10.1016\/S0021-9258(18)42852-9"},{"key":"2019111703043817900_R53","doi-asserted-by":"crossref","unstructured":"Castaman G, Tosetto A, Rodeghiero F. Shortened von Willebrand factor survival: pathophysiologic and clinical relevance. J Thromb Haemost. 2009;7(Suppl 1):71\u201374.","DOI":"10.1111\/j.1538-7836.2009.03381.x"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/113\/645564\/113_123ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/113\/645564\/113_123ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T23:40:45Z","timestamp":1634341245000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/113\/19865\/Optimizing-treatment-of-von-Willebrand-disease-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.113","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}